Gaxos.ai (NASDAQ:GXAI – Get Free Report) and Chemed (NYSE:CHE – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
Profitability
This table compares Gaxos.ai and Chemed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gaxos.ai | -64.81% | -38.79% | -36.99% |
| Chemed | 10.60% | 31.77% | 18.90% |
Earnings and Valuation
This table compares Gaxos.ai and Chemed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gaxos.ai | $6.01 million | 1.07 | -$3.90 million | ($0.50) | -1.19 |
| Chemed | $2.60 billion | 2.50 | $265.24 million | $19.91 | 24.89 |
Chemed has higher revenue and earnings than Gaxos.ai. Gaxos.ai is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Gaxos.ai has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Institutional & Insider Ownership
42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 95.8% of Chemed shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings for Gaxos.ai and Chemed, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gaxos.ai | 1 | 0 | 0 | 0 | 1.00 |
| Chemed | 0 | 5 | 1 | 0 | 2.17 |
Chemed has a consensus price target of $530.75, suggesting a potential upside of 7.10%. Given Chemed’s stronger consensus rating and higher probable upside, analysts plainly believe Chemed is more favorable than Gaxos.ai.
Summary
Chemed beats Gaxos.ai on 13 of the 14 factors compared between the two stocks.
About Gaxos.ai
Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Gaxos.ai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gaxos.ai and related companies with MarketBeat.com's FREE daily email newsletter.
